Abbott licenses Reata's CKD candidate outside the US for $450 million
This article was originally published in Scrip
Abbott Laboratories and Reata Pharmaceuticals have entered into a collaboration agreement to develop and commercialise bardoxolone methyl, which is currently in late Phase II trials for the treatment of chronic kidney disease (CKD).
You may also be interested in...
Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.